b'KERENDIA is therst and only selective In adult patients with CKD associated with T2D non-steroidal MRA proven to provide dual cardiorenal risk reduction in adult patients KERENDIA is a fundamentalwith CKD associated with T2D 1pillar in the treatmentKERENDIA blocks MR overactivation, which is thought to lead to in ammation andbrosis 1 KERENDIA has proven ef cacy and safety in patients with T2D algorithm to improve CV 1with a broad range of CKD severityand renal outcomes 1Visit the KERENDIA Criteria for Use (CFU) arewebsite to learn more INDICATION: available for KERENDIAabout our latest KERENDIA is indicated to reduce the risk of sustained eGFRcardiovascular data decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failureDRUG INTERACTIONS:in adult patients with chronic kidney disease (CKD) associatedStrong CYP3A4 Inhibitors:with type 2 diabetes (T2D)Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juiceIMPORTANT SAFETY INFORMATION Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage CONTRAINDICATIONS:adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor and adjust KERENDIAConcomitant use with strong CYP3A4 inhibitorsdosage as appropriate Strong and Moderate CYP3A4 Inducers: Patients with adrenal insuf ciencyAvoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducersWARNINGS AND PRECAUTIONS: USE IN SPECIFIC POPULATIONS:Hyperkalemia:KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increasesLactation: with decreasing kidney function and is greater in patients with higher baseline potassium levelsAvoid breastfeeding during treatment with KERENDIA and for 1 day after treatment or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients beforeHepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serumPugh C) and consider additional serum potassium monitoring with moderate hepatic impairment potassium is 5.0 mEq/L(Child Pugh B) Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly.Please read the Brief Summary of the KERENDIA Prescribing Information on the following page.More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassiumCKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerularltration rate; MR, mineralocorticoid receptor; MOST COMMON ADVERSE REACTIONS: MRA, mineralocorticoid receptor antagonist; T2D, type 2 diabetes. From the pooled data of 2 placebo-controlled studies, the adverse reactions reported in 1% of patients onReference: 1. KERENDIA [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc; September 2022. KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs2022 Bayer. BAYER, the Bayer Cross, and KERENDIA are registered trademarks of Bayer.3.9%), and hyponatremia (1.3% vs 0.7%) All rights reserved. MAC-KER-US-0122-1 11/22'